Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 10/20 | 0.40 |
| ▸ | CCND1 | P24385 | 7/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.37 |
| ▸ | CDK2 | P24941 | 6/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213302 | 1.00 | MAPK3 (0.40) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL27213279 | 0.88 | MAPK3 (0.40) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL31164172 | 0.88 | MAPK3 (0.40) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL29821030 | 0.86 | CDK4 (0.43) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL27390146 | 0.86 | CDK4 (0.43) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL22997722 | 0.86 | CDK4 (0.43) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL22900954 | 0.86 | CDK4 (0.43) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL27213261 | 0.85 | CCND1 (0.38) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL27213269 | 0.85 | CCND1 (0.38) | MAPK3CCND1CDK6CDK4CCND3 | |
| SCHEMBL21178194 | 0.82 | MAPK3 (0.55) | MAPK3CCNKCDK12ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11939340-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023141571-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230234964-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-07-27 | — | — | US | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| EP-4013750-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939340-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | MAPK3 300/4885CCND1 46/4885CDK6 1/4885 |
| US-20230234964-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | MAPK3 300/4885CCND1 46/4885CDK6 1/4885 |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | MAPK3 363/4885CCND1 54/4885CDK6 12/4885 |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | MAPK3 300/4885CCND1 46/4885CDK6 1/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | MAPK3 363/4885CCND1 54/4885CDK6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.